Key facts
- It has raised $44.7M; the latest was Later Stage VC in Oct 2024.
- Notable investors include Emerald Development Managers, The Nucleus Network, Becton, Dickinson and Company, Lago Consulting & Services — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Babson Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Babson Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Babson Diagnostics
Operator of a healthcare technology company intended to offer diagnostic blood testing at the retail pharmacy counters. The company's technology is designed to produce accurate diagnostic results from small capillary samples collected at convenient retail locations and analyzed at CLIA-certified clinical laboratories, enabling consumers to get laboratory-grade blood diagnoses done within a short wait time.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 55
- Website
- betterway.com/
- Ownership
- Privately Held (backing)
Babson Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Babson Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Babson Diagnostics in its N-PORT filings yet. We sweep new filings monthly.